Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs
Mark Heaney(Immunovaccine (Canada)), Owen A. O’Connor(Virginia Cancer Institute)
Cited by 222
Related Papers
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
|Blood|2020|397
Avapritinib versus Placebo in Indolent Systemic Mastocytosis
|NEJM Evidence|2023|74